Business
Oculis to Host an R&D Retina Day to Showcase Clinical Programs Targeting Diabetic Macular Edema and Other Retina Diseases on Tuesday, July 11, 2023
R&D Retina Day featuring several retina experts will take place from 10:00 AM – 12:00 PM EDT at the Lotte New York Palace Hotel and onlineCo-principal
About this update from Oculis Holding Ag
[{"type":"text","content":"R&D Retina Day featuring several retina experts will take place from 10:00 AM – 12:00 PM EDT at the Lotte New York Palace Hotel and onlineCo-principal investigators, Dr. David S. Boyer and Dr. Arshad M. Khanani, for Phase 3 DIAMOND trial of OCS-01 eye drops in Diabetic Macular Edema (DME) will discuss recent Stage 1 readout and plans for next stepsDr. Quan Dong Nguyen to highlight clinical proof-of-concept (PoC) LEOPARD trial of OCS-01 eye drops in Cystoid Macular Edema (CME)Neuro-ophthalmology expert Dr. Sophie Bonnin will discuss clinical PoC ACUITY trial of OCS-05 in Acute Optic Neuritis (AON)Click here to register to attend the event either in-person or virtually ZUG, Switzerland and BOSTON, June 26, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that it will host its first R&D Day featuring multiple experts to showcase its clinical programs targeting retina diseases on Tuesday, July 11, 2023, from 10:00 AM – 12:00 PM EDT. Those interested can participate in the event either in-person at the Lotte New York Palace Hotel, or virtually via webcast. To register for the event, please click here. Topics to be covered by retina specialists and the Oculis management team during the event include the unmet medical needs and current treatment landscapes in Diabetic Macular Edema (DME), Cystoid Macular Edema (CME), and Acute Optic Neuritis (AON), as well as: OCS-01 DME DIAMOND program: The recent Stage 1 read-out of the DIAMOND trial and plans for the upcoming DIAMOND 1 and DIAMOND 2 trialsOCS-01 CME LEOPARD trial: The PoC LEOPARD trial initiation of OCS-01 eye drops in CMEOCS-05 AON ACUITY trial: The ongoing PoC ACUITY trial of OCS-05, a neuroprotective candidate with a novel mechanism of action, in Acute Optic Neuritis Retina experts participating in the event include: Sophie Bonnin, MD: Neuro-retina specialist at the Foundation Rothschild Hospital, Paris, with clinical expertise in retina, neuro-ophthalmology and clinical imagingDavid S. Boyer, MD: Co-principal investigator of the DIAMOND trial; Partner, Retina Vitreous Associates Medical Group; Adjunct Clinical Professor of Ophthalmology at the University of Southern California Keck School of Medicine; Oculis Scientific Advisory Board (SAB) memberQuan Dong Nguyen, M...